^
Association details:
| Biomarker: | CIP2A rs13069780 |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The role of PP2A variants to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and TRIBE trials.
Published date:
05/19/2021
Excerpt:
...pts carrying CIP2A rs13069780 C/C (N=24) only showed significantly longer progression-free survival (17.7 vs 12.3 months) than carriers of any T allele...Meanwhile CIP2A polymorphism could predict outcomes of cet-based treatment in mCRC patients.
DOI:
10.1200/JCO.2021.39.15_suppl.3581
